
1/3 🧬 Our review is out in @NatureRevMicro! How can we develop #antibiotics that remain effective as bacteria evolve? Our answer: make #resistance evolution part of drug development from the very beginning.

The lab's interest includes antibiotic resistance, systems biology, and microbial experimental evolution. Account run by lab members. @csabapallab.bsky.social

1/3 🧬 Our review is out in @NatureRevMicro! How can we develop #antibiotics that remain effective as bacteria evolve? Our answer: make #resistance evolution part of drug development from the very beginning.


3/3 Predicting resistance early could save years of research, reduce costly failures and guide the design of more durable antibiotics. Science is advancing. Drug development cannot afford to keep treating evolution as an afterthought. Our new review: nature.com/articles/s41579-0….

2/3 GSK2251052 is a striking example: resistance emerged during phase II clinical trials, leading to the discontinuation of its development for systemic Gram-negative infections in 2012. Could earlier evolutionary testing have changed its trajectory?

1/3 💊 A promising antibiotic can survive years of development, only to fail when bacteria evolve resistance. Yet resistance evolution is still too often assessed late in drug development, when opportunities to intervene are limited.


3/3 These findings inform five main resistance-risk categories, helping developers decide which compounds to prioritise, optimise or use more selectively. Evolutionary insight can guide drug design. doi.org/10.1038/s41579-026-0… #evolution #AntibioticResistance #DrugDiscovery

2/3 Five questions guide the assessment: 1. How easily can resistance evolve? 2. Does it weaken bacteria or increase virulence? 3. Will resistance persist? 4. Could it compromise other antibiotics? 5. How risky are the resistance genes?

1/3 🔬 Can we assess an antibiotic’s evolutionary future before clinical trials? Our new review proposes a five-step framework built around five key dimensions of resistance risk.

3/3 The goal is not just to develop antibiotics that work today, but to anticipate how bacteria might escape them tomorrow. Read our review here: doi.org/10.1038/s41579-026-0… #AntibioticResistance #DrugDiscovery

2/3 Together, Csaba Pál, Petra Szili and Szilvia Juhász from @BiologicalRese1 and @HcemmSzeged propose a practical five-step #framework to assess evolutionary risks, prioritise promising compounds and guide antibiotic design.

3/3 The goal is not just to develop antibiotics that work today, but to anticipate how bacteria might escape them tomorrow. Read our review: doi.org/10.1038/s41579-026-0… #AntibioticResistance #DrugDiscovery

2/3 Together, Csaba Pál, Petra Szili and Szilvia Juhász from @BiologicalRese1 and @HcemmSzeged propose a practical five-step #framework to assess evolutionary risks, prioritise promising compounds and guide #AntibioticDesign.

Warm congratulations to the @research_lazar and Szilvia Juhasz teams! A well-deserved recognition to have your work featured in the Editors’ Highlights at @NatureComms ! 👏
Thrilled to see our MALVINA study selected for @NatureComms Editors’ Highlights in Microbiology and Infectious Diseases! Our work reveals how bacterial interactions and antibiotics reshape pathogen virulence at the single-cell level. nature.com/collections/jedgc…

📢 Paper Alert! Grateful to have been involved in this amazing work by @research_lazar and SzilviaJuhasz labs, presenting a framework for dissecting pathogen-host-drug interactions. #Pathogen #Virulence #SingleCell #DeepLearning @SysbioS Check it at: shorturl.at/LQUFP 👇
Counting bacteria is not enough. To understand what makes a bacterium dangerous, we need to see what it actually does when it meets human cells. Our MALVINA study is now out in @NatureComms

After the conference, we also had the chance to visit Isabel Gordo @gordoisabel1 and her lab. A huge thank you for the warm welcome, the inspiring conversations, and an excellent few days of science. We had a fantastic time at GIMM Fest!